5608
C. F. Klitzke, R. A. Pilli / Tetrahedron Letters 42 (2001) 5605–5608
14. For the synthesis of 8a-epi-lentiginosine, see: Paolucci,
7. For the use of InCl3 as Lewis acid in N-acyliminium
C.; Musiani, L.; Venturelli, F.; Fava, A. Synthesis 1997,
1415–1418.
chemistry, see: Russowsky, D.; Petersen, R. Z.; Godoi,
M. N.; Pilli, R. A. Tetrahedron Lett. 2000, 41, 9939–9942.
8. (a) Keck, G. E.; Abbott, D. E. Tetrahedron Lett. 1984,
25, 1883–1886; (b) Keck, G. E.; Abbott, D. E.; Boden, E.
P.; Enholm, E. J. Tetrahedron Lett. 1984, 25, 3927–3930;
(c) Marshall, J. A.; Hinkle, K. W. J. Org. Chem. 1995,
60, 1920–1921.
9. Cieplak, A. S. Chem. Rev. 1999, 99, 1265–1336.
10. For better results in the syn addition of TBS protected
tartaric imide, see: Ryu, Y.; Kim, G. J. Org. Chem. 1995,
60, 103–108.
11. For some examples of ring-closing metathesis applied to
the synthesis of nitrogen heterocycles, see: (a) Martin, S.
F.; Chen, H. J.; Courtney, A. K.; Liao, Y.; Pa¨tzel, M.;
Ramser, M. N.; Wagman, A. S. Tetrahedron 1996, 52,
7251–7264; (b) Tarling, C. A.; Holmes, A. B.; Markwell,
R. E.; Pearson, N. D. J. Chem. Soc., Perkin Trans. 1
1999, 1695–1701; (c) Maldaner, A. O.; Pilli, R. A. Tetra-
hedron Lett. 2000, 41, 7843–7846.
12. For the synthesis of 1-hydroxyindolizidine, see: (a) Har-
ris, C. M.; Harris, T. M. Tetrahedron Lett. 1987, 28,
2559–2562; (b) Harris, C. M.; Schneider, M. J.;
Ungemach, F. S.; Hill, J. E.; Harris, T. M. J. Am. Chem.
Soc. 1988, 110, 940–949; (c) Takahata, H.; Banba, Y.;
Momose, T. Tetrahedron: Asymmetry 1990, 1, 763–764.
13. For other synthetic approaches to lentiginosine, see: (a)
Yoda, H.; Kitayama, H.; Katagiri, T.; Takabe, K. Tetra-
hedron: Asymmetry 1993, 4, 1455–1456; (b) Nukui, S.;
15. All new compounds gave spectral and analytical data in
accordance with the proposed structures. Compound 8:
[h]2D6 +14.3 (c 2.37, CHCl3); IR (neat) 3037, 2929, 2848,
1
1737, 1699, 1656, 1440, 1375, 1236, 1055; H NMR (300
MHz, CDCl3): l 1.95–2.09 (m, 1H), 2.05 (s, 3H), 2.37–
2.47 (m, 2H), 2.77 (dd, J 8.1 and 18.4 Hz, 1H), 3.50–3.57
(m, 2H), 4.32 (dd, J 2.7 and 18.4 Hz, 1H), 4.94 (dt, J 2.5
and 7.7 Hz, 1H), 5.64–5.68 (m, 1H), 5.73–5.78 (m, 1H);
13C NMR (75 MHz, CDCl3): l 20.72, 28.62, 36.30, 39.85,
59.28, 71.67, 123.77, 123.81, 170.63, 170.66; HRMS (EI)
calcd for C10H13NO3 (M+.) 195.0895, found 195.0895.
Compound 17: [h]2D4 +94.5 (c 1.35, CHCl3); IR (neat)
3016, 2936, 2852, 1749, 1725, 1653, 1432, 1371, 1239,
1
1058; H NMR (300 MHz, CDCl3): l 2.13 (s, 3H), 2.16
(s, 3H), 2.19–2.26 (m, 1H), 2.57 (dl, J 16.8 Hz, 1H), 3.51
(dt, J 4.6 and 10.5 Hz, 1H), 3.64 (d, J 18.8 Hz, 1H), 4.33
(dd, J 2.9 and 18.8 Hz, 1H), 5.08 (dd, J 5.1 and 5.3 Hz,
1H), 5.46 (dd, J 1.4 and 5.3 Hz, 1H), 5.72–5.75 (m, 1H),
5.82–5.85 (m, 1H); 13C NMR (75 MHz, CDCl3): l 20.67,
20.75, 30.02, 40.16, 55.22, 74.39, 77.69, 122.29, 123.53,
166.44, 170.00, 170.36; HRMS (EI) calcd for C12H15NO5
(M+.) 253.0950, found 253.0950. Compound 18: [h]2D4
+167.1 (c 1.12, CHCl3); IR (neat) 3040, 2935, 2858, 1744,
1
1715, 1595, 1433, 1375, 1256, 1069; H NMR (300 MHz,
CDCl3): l 2.01–2.19 (m, 2H), 2.14 (s, 3H), 2.17 (s, 3H),
3.61 (d, J 18.3 Hz, 1H), 4.02 (ddd, J 4.4, 6.9 and 11.2 Hz,
1H), 4.38 (dd, J 2.9 and 18.3 Hz, 1H), 5.43–5.50 (m, 2H),
5.70–5.74 (m, 1H), 5.80–5.87 (m, 1H); 13C NMR (75
MHz, CDCl3): l 20.37, 20.51, 24.95, 40.46, 52.35, 72.71,
73.71, 123.59, 123.84, 165.98, 170.09, 170.44; HRMS (EI)
calcd for C12H15NO5 (M+.) 253.0950, found 253.0956.
Spectral and analytical data of 9, 19, and 20 are in
agreement with those described in Refs. 12, 13 and 14,
respectively.
Sodeoka, M.; Sasai, H.; Shibasaki, M. J. Org. Chem.
.
1995, 60, 398–404; (c) Brandi, A.; Cicchi, S.; Cordero, F.
M.; Frignoli, R.; Goti, A.; Picasso, S.; Vogel, P. J. Org.
Chem. 1995, 60, 6806–6812; (d) Ha, D. C.; Yun, C. S.;
Lee, Y. J. Org. Chem. 2000, 65, 621–623; (e) Yoda, H.;
Katoh, H.; Ujihara, Y.; Takabe, K. Tetrahedron Lett.
2001, 42, 2509–2512.